FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma. Brave MH, Maguire WF, Weinstock C, Zhang H, et al. Clin Cancer Res 2024;30:4815-4821.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Brave MH, Maguire WF, Weinstock C, Zhang H, et al. FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res 2024;30:4815-4821.
PMID: 39230571